AL
AXDX icon

Airain Ltd’s Accelerate Diagnostics AXDX Stock Holding History

Airain Ltd’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-946
Closed -$203K – 796
2015
Q4 		$203K Buy
+946
New +$173K 0.01% 723

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
JP Morgan Private Wealth Advisors
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Airain Ltd's AXDX Position: Q1 2016 in Review

Airain Ltd sold out of Accelerate Diagnostics (AXDX) in Q1 2016, closing a stake of 946 shares — an estimated $203K sold.

Airain Ltd first reported a position in AXDX in Q4 2015 and held it in 1 quarter. The position peaked at $203K in Q4 2015. 92 funds tracked by Wall St. Rank hold AXDX as of Q1 2016.

  • Airain Ltd reported no remaining Accelerate Diagnostics position as of Q1 2016 after selling out during the quarter.
  • Airain Ltd sold 946 Accelerate Diagnostics shares in Q1 2016, an estimated $203K.
  • Airain Ltd first reported a position in Accelerate Diagnostics in Q4 2015 and held it in 1 quarter.
  • Airain Ltd's Accelerate Diagnostics position peaked at $203K in Q4 2015.
  • 92 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2016.

Based on Airain Ltd's 13F filing for Q1 2016, filed 9 May 2016.